Haemophilia therapeutics - Aanastra
Latest Information Update: 19 May 2024
At a glance
- Originator Aanastra
- Class Antihaemorrhagics; Peptides; RNA
- Mechanism of Action Factor VIII stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haemophilia A